CAMP4 Therapeutics Corporation (CAMP) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CAMP scores 25 out of 100 for a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC -35%; FCF yield -12.19%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 5/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). Every pillar sits at or below 8 of 20, so the rating reflects weakness across cash generation, ownership signals, insider behavior, macro fit, and balance-sheet health rather than a single isolated concern. For a prospective investor, the upside case rests almost entirely on a future shift in cash generation or on a catalyst the source data does not quantify, while the valuation tradeoff is that the stock trades on a price-to-sales-free basis with negative operating margin of -60% and negative FCF. The rating is an analytical summary of the source data and is not personalized advice.

Per the source profile, CAMP4 Therapeutics Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is listed as $0.2B. The source data does not describe its products, customers, or revenue model in detail. Reported revenue of $3.5M in FY 2025 indicates a small top line relative to its operating losses.

Per the SEC financials, operating losses have remained in the $-51.9M to $-53.1M range across the three periods, with FY 2025 operating income at $-52.6M and net income widening to $-80.4M. Market data reports gross margin at 0%, operating margin at -60%, net margin at -60%, and ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5, which together point to a weak forensic balance-sheet posture. Reported cash rose to $109.5M in FY 2025 from $64.0M in FY 2024.

Per the recent news feed, the most recent items include a Yahoo Finance report referencing a possible negative earnings outcome ahead of a Q3 release, and a Raymond James initiation with a Strong Buy rating and $10 price target reported via marketscreener.com. A Stock Titan item reports that the EU approved a trial of a potential treatment for SYNGAP1-related disorder, which is the only item flagged GREEN with a CATALYST impact label. A Bull Pennant-labeled item reports the shares climbing 4.17% to $4.00 while pressing against the upper range. Other items (TradingView, Yahoo Finance Canada) are chart or market-data pages with no fundamental content. Per the Butterfly Supply-Chain Graph, the sector is Health Care and the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What are the specific products or clinical programs generating the $3.5M in FY 2025 revenue, and who the counterparties are?
• What is the cash runway implied by the $109.5M cash balance against operating losses of $-52.6M in FY 2025?
• What drove the widening of net income from $-51.8M in FY 2024 to $-80.4M in FY 2025?
• What is the current debt position, since the source reports debt as N/A while citing Debt/Equity of 0.5?
• What is the status and timing of the EU-approved SYNGAP1 trial, and how does it affect the Q3 earnings expectation?